Stelis's small-scale cGMP manufacturing facility is designed to support smallscale commercial and cGMP clinical trial material generation
Site has a capital investment program of ~$30 million spent or committed over the last three years to expand capabilities and improve operational efficiencies
The inspection was a Pre-Approval cum cGMP inspection and it covered 15 ANDAs
ICICI Direct expects revenue CAGR of 35.6% over FY22-FY24E mainly due to the consolidation of Viatris business and they expect EBITDA margin expansion of 230bps and earnings CAGR of 64.8% over FY22-FY24E
Dr Rupali Paranjape, an experienced regulatory and compliance consultant and author of Blue Ocean of Compliance shares insights on her book in an interview with Thomas C Thottathil, Editor, www.indianpharmapost.com
A total of five observations for Goa and 17 for Monroe
The vaccine was found to have 64% efficacy against symptomatic disease and 92% against severe Covid-19
It is part of the company's CAD $30 million capital investment in the Aurora, Canada site
Anand Rathi maintains long-term guidance of 10-15% revenue growth and 40% EBITDA margins
The unit is an oral manufacturing facility at Jedcherla, Hyderabad
Subscribe To Our Newsletter & Stay Updated
